Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in May. 2026,
Vector Science and Therapeutics receivedC$2.17 Mil more from issuing new shares than it paid to buy back shares.
It receivedC$0.00 Mil from issuing more debt.
It paidC$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedC$0.00 Mil from paying cash dividends to shareholders.
It spentC$0.59 Mil on other financial activities.
In all, Vector Science and TherapeuticsearnedC$1.58 Mil on financial activities for the
three
months ended in May. 2026.
Vector Science and Therapeutics (TSXV:PAIN) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Vector Science and Therapeutics's issuance of stock for the
three
months ended in May. 2026 was C$2.17 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Vector Science and Therapeutics's repurchase of stock for the
three
months ended in May. 2026 was C$0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Vector Science and Therapeutics's net issuance of debt for the
three
months ended in May. 2026 was C$0.00 Mil.
Vector Science and Therapeutics receivedC$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Vector Science and Therapeutics's net issuance of preferred for the
three
months ended in May. 2026 was C$0.00 Mil.
Vector Science and Therapeutics paidC$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Vector Science and Therapeutics's cash flow for dividends for the
three
months ended in May. 2026 was C$0.00 Mil.
Vector Science and Therapeutics receivedC$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Vector Science and Therapeutics's other financing for the
three
months ended in May. 2026 was C$-0.59 Mil.
Vector Science and Therapeutics spentC$0.59 Mil on other financial activities.
Vector Science and Therapeutics Cash Flow from Financing Related Terms
Vector Science and Therapeutics Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics Cash Flow from Financing Chart
Vector Science and Therapeutics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of C$1.68 Mil mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Cash Flow from Financing of C$1.68 Mil as of May. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' Cash Flow from Financing too high?
Vector Science and Therapeutics' current Cash Flow from Financing is C$1.68 Mil. Overall, Vector Science and Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Cash Flow from Financing compare to ABT and SYK?
Vector Science and Therapeutics' Cash Flow from Financing of C$1.68 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current Cash Flow from Financing is C$1.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Cash Flow from Financing of C$1.68 Mil. The current Cash Flow from Financing is C$1.68 Mil. Vector Science and Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Cash Flow from Financing is C$1.68 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
15GF Score
Get the complete analysis for TSXV:PAIN
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PAIN has been successfully added to your 
